Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a 15 amino-acid sequence — derived from a naturally occurring protein found in human gastric juice. It was isolated and studied extensively by researchers at the University of Zagreb, primarily the group led by Dr. Predrag Sikiric, beginning in the 1990s. To date, the published research on BPC-157 consists predominantly of preclinical studies in animal models, with no completed large-scale randomized controlled trials in humans. Understanding this evidence base is essential for any informed discussion of its potential applications.
Preclinical Research Overview
In rat models, BPC-157 administered locally or systemically accelerated the healing of transected Achilles tendons, with histological evidence of improved collagen organization and earlier vascularization compared to controls. The authors proposed upregulation of growth hormone receptor expression as a contributing mechanism.
Sikiric's group has published extensively on BPC-157's effects on gastric and intestinal mucosal integrity in rodent models of NSAID-induced ulceration, inflammatory bowel disease, and bowel anastomosis healing. BPC-157 appears to activate the nitric oxide (NO) pathway and modulate prostaglandin synthesis to support mucosal defense.
In rat models of bone fracture and muscle crush injury, systemic BPC-157 was associated with accelerated callus formation and faster return of muscle function compared to saline controls, alongside upregulated expression of genes related to the extracellular matrix remodeling.
BPC-157 was found to promote angiogenesis through upregulation of VEGFR2, EGF, and related growth factors in a series of wound-healing studies. Increased vascular density in treated wounds correlated with faster tissue closure in animal subjects.
Proposed Mechanisms
- Nitric oxide pathway modulation: BPC-157 appears to stimulate endothelial NO synthase (eNOS), promoting vasodilation and tissue perfusion.
- Growth factor upregulation: Evidence from animal studies suggests interactions with EGF, VEGF, and growth hormone receptor signaling pathways.
- Cytokine regulation: Anti-inflammatory signaling in preclinical GI models, potentially relevant to systemic inflammatory states.
- Extracellular matrix remodeling: Collagen synthesis and organization appear enhanced in multiple tissue types studied in rodents.
Evidence Limitations
It is important to acknowledge that virtually all published BPC-157 research is preclinical. Animal models of tissue healing do not always translate directly to human physiology, and the bioavailability, dosing, and safety profile of BPC-157 in humans have not been established through rigorous clinical trials. No BPC-157 product is currently FDA-approved. Any clinical use occurs in the context of compounded prescriptions from licensed 503A pharmacies, prescribed off-label by licensed physicians who weigh available evidence against individual patient circumstances.
References
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. 2011;17(16):1612-32.
- Staresinic M, et al. Gastrointestinal tract healing as influenced by BPC 157. J Physiol Paris. 2001;95(1-6):139-41.
- Novinscak T, et al. Effect of BPC 157 on Muscle and Bone Healing. J Orthop Res. 2008.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774-80.
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.